WO1999062503A2 - Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases - Google Patents

Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases Download PDF

Info

Publication number
WO1999062503A2
WO1999062503A2 PCT/EP1999/003625 EP9903625W WO9962503A2 WO 1999062503 A2 WO1999062503 A2 WO 1999062503A2 EP 9903625 W EP9903625 W EP 9903625W WO 9962503 A2 WO9962503 A2 WO 9962503A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
heteroatoms
substituted
chain
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/003625
Other languages
French (fr)
Other versions
WO1999062503A3 (en
Inventor
Gerhard Eisenbrand
Ralph HöSSL
Doris Marko
Weici Tang
Laurent Meijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98109845A external-priority patent/EP0966963A1/en
Priority to BR9910810-0A priority Critical patent/BR9910810A/en
Priority to AT99926420T priority patent/ATE233560T1/en
Priority to AU43687/99A priority patent/AU762830B2/en
Priority to CA002333661A priority patent/CA2333661A1/en
Priority to DK99926420T priority patent/DK1079826T3/en
Priority to EP99926420A priority patent/EP1079826B1/en
Priority to KR1020007013499A priority patent/KR20010078722A/en
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2000551759A priority patent/JP2002516851A/en
Priority to DE69905712T priority patent/DE69905712T2/en
Priority to IL13991499A priority patent/IL139914A0/en
Priority to HU0102240A priority patent/HUP0102240A3/en
Publication of WO1999062503A2 publication Critical patent/WO1999062503A2/en
Publication of WO1999062503A3 publication Critical patent/WO1999062503A3/en
Priority to NO20006027A priority patent/NO20006027L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and CDK 5, more particularly ATP:Proteinphosphotransfer- ase p34 cdc2 (CDK1 ) .
  • Indigoid bisindoles comprise a spectrum of natural dye stuffs. Many of these can be obtained from plants. Accordingly, indirubine, indigo and isoindigo are natural products which can be obtained from different plants: namely, Baphicacanthus cusia (Acanthaceae), Indigofera suffruticosa (Fabaceae), Isatis indigotica (Brassi- caceae) and others.
  • Indican a glycoside which is found in plants, gives glucose and 3-hydroxyindole due to acidic or enzymatic hydrolysis. 3-Hydroxyindole is converted by air-oxidation into indigo and its isomers.
  • Indigo naturalis is the natural blue dye obtained from plant material, e.g. Isatis indigotica (Brassicaceae) .
  • Indirubine an isomer of indigo, can be found in Indigo natura- Ms in an amount of up to 60% (Falbe J . & Regitz M., R ⁇ mpp Chemie Lexikon
  • Indigo naturalis is reported to be used in traditional Chinese medicine ⁇ s a hemostatic, antipyretic, anti-inflammatory and sedative agent in the treatment of bacterial and viral infections. Antileukemic effects of Indigo naturalis have also been reported, with indirubine being the effective principle (Ji X. et al., Acta Pharm. Sin., 1 6, ( 1 981 ), 146-1 48; Gan W. J . et al., J . Hematol., 6, (1 985), 61 1 -61 3) . Furthermore, derivatives of indirubine are known for a long time as dyes of low persistence. Few, structurally quite different types of p34 cdc2 inhibitors have been described up to now.
  • Staurosporine an alkaloid from Streptomyces sp
  • Butyrolactone-I from Aspergillus terreus var.
  • Flavopiridol a novel promising anti-tumour agent derived by partial synthesis from a parent structure found in the indian plant Dysoxylum binectariferum, 9- Hydroxyellipticin from the plants Ochrosia elliptica and Ochrosia acuminata, the purine derivatives olomoucine, roscovitine and isopentenyladenine and some peptides.
  • the mechanism of these compounds is based on competitive inhibition of ATP binding (Meijer , Trends in Cell Biology, 6, (1 996), 393-397) .
  • p34 cdc2 /cyclin B was purified from M phase starfish (Marthasterias glacialis) oocytes by affinity chromatogaphy on p9 CKShs1 -Sepharose beads, from which it was eluted by free p 9 CKShs1 as described (Meijer et al., Eur. J. Biochem., 243, (1 997), 527-536) .
  • the wet filters were transferred into 6 ml plastic scintillation vials, 5 ml ACS (Amersham) scintillation fluid was added and the radioactivity measured in a Packard scintillation counter.
  • the kinase activity was expressed in pmoles phosphate incorporated into histone H 1 /10 min incubation or in % of maximal activity.
  • the strongest inhibitors of p34 are derivatives of staurosporine (IC 50
  • CDK cyclin-dependent kinase
  • EGF-R epidermal growth factor receptor tyrosine kinase
  • l-R insulin receptor-tyrosine kinase
  • MAPK mitogene-activated protein kinase
  • ND not determined
  • PKA cAMP-dependent protein kinase
  • PKG cGMP-dependent protein kinase
  • IC 50 -value for racemic mixture IC 50 for (R)-roscovitin is 0.45 ⁇ M.
  • Cyclins and cyclin dependent kinases have an essential role for driving the cell through the cell cycle (cell division cycle, cdc) .
  • cell division cycle oscillations in concentrations and activities of cyclins are observed. This applies, e.g. to cyclins D and E in the so-called G 1 -phase of the cell cycle and to cyclinA (S- and M-Phase) and cycIinB (G2- and M-Phase) .
  • CDK1 p34 cdc2
  • CDK2 CDK8
  • CDK-proteins consist of a catalytic subunit and a regulatory subunit, the cyclins (Meijer et al., Eur. J. Biochem., 243, ( 1 997), 527-536) . Every step of the cell division cycle is regulated by specific CDK/cyc- lin complexes which ascertain a strict control.
  • Important checkpoints are at the transition from G 1 phase to S phase and from G2 phase to M phase (Pines J., Cancer Biology, 6, (1 995), 63-72).
  • the p34 cdc2 /cyclinB complexes are important components at the G 2 -M-checkpoint.
  • the cdc2/cyclinB complexes are the primary active protein kinases in mitosis. They accumulate in an inactive state in the cytoplasm in interphase cells, and are then rapidly activated by cdc25 phosphatase and translocated into the nucleus at the beginning of mitosis (Pines J., Hunter J., Cell Biol., 1 1 5(1 ) , ( 1 991 ), 1 -1 7) . CyclinB is degraded at the metaphase-anaphase transition, inactivating cdc2, which is necessary for exit from mitosis (Glotzer et al., Nature, 349(6305). (1 991 ), 132-138; Murray A.W., Nature, 339(6222). (1 989), 280-286; Surana U. et al., Cell, 65(1). (1 991 ), 145-1 61 ) . Multiple changes of
  • CDK proteins and their regulators are associated with the development of human tumours (Cordon-Cardo C, Am. J. Pathol., 147(3), (1 995), 545-560) .
  • the technical problem underlying the present invention is to provide new inhibitors for cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and
  • CDK 5 more particularly ATP:Proteinphosphotransferase p34 cdc2 (CDK1 ), which exhibit a high selectivity as well as high efficiency compared to the inhibitors known in the art.
  • the present invention relates to the use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and CDK 5, more particularly
  • the indigoid bisindole derivatives are selected from indigo derivatives, isoindigo derivatives or indirubine derivatives.
  • the indirubine derivate is a compound having the general formula (I)
  • R 1 and R 6 can be the same or different and represent a hydrogen atom; a halogen atom; a hydroxy group; a methylenehydroxy group; a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain alkyloxy group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain methylenealkoxy group having 1 to 18 carbon atoms; a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; a substituted or unsubstituted aralkyl group which can comprise one or more heteroatoms; a substituted or unsubstituted aryloxy group which can comprise one or more heteroatoms; a mono-, di- or trialkylsilyl group having 1 to 6 carbon atoms independently of each other
  • one or more ring atoms can be replaced by nitrogen atoms.
  • one or more aromatic or non-aromatic ring systems which can comprise one or more heteroatoms independently of each other, can be condensed to the indirubine system.
  • the indirubine derivatives having the above general formula (I) can also be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
  • the isoindigo derivate is a compound having the general formula (II)
  • R 1 to R 14 and X and Y have the above definitions.
  • the isoindigo derivates of the above general formula (II) one or more ring atoms can be replaced by nitrogen atoms. Further, one or more aromatic or non-aromatic ring systems which can comprise one or more heteroatoms independently of each other, can be condensed to the isoindigo system. Furthermore, the isoindigo derivatives having the above general formula (II) can be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
  • the indigo derivate is a compound having the general formula (III)
  • R 1 to R 14 and X and Y have the above definitions.
  • the indigo derivatives having the above general formula (III) can be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
  • indigoid bisindole derivatives are highly selective inhibitors of the enzyme complex p34 cdc2 /cyclinB.
  • An inhibition of p34 cdc2 -kinase by indigoid bisindole derivatives is not described in the prior art.
  • indigoid bisindole derivatives are both highly selective and highly effective inhibitors of cdc2-kinase and other cyclin dependent kinases (CDK's), showing IC 50 -values with the isolated enzyme down to submicromolar range.
  • CDK-activities also is observed in cell culture, using human tumor cell lines.
  • indirubin-3'-monoxime was found to inhibit histone H 1 phosphorylation as a measure for CDK1 /cyclin B activity after 24 h incubation of MCF-7 mammary carcinoma cells.
  • the content of cyclin B complex was significantly reduced.
  • Cells arrested by serum deprivation after treatment for 24 h with indirubin-3'-monoxime in serum containing medium exhibited an arrest in G 1 -phase of the cell cycle at low micromolar concentrations of the substance. In concentrations > 5 ⁇ M, an additional arrest at G2/M-phase of the cell cycle became apparent.
  • indirubine derivatives can be used for analytical biochemistry, especially for the study of cell cycle effects. Furthermore, these compounds can be used for the treatment of diseases in patients, which are connected to the loss of proliferation control without any restriction to these potential areas of application. These include cancers, psoriasis, cardiovascular diseases (stenosis, restenosis) (Brooks et al., J. Biol.
  • Example 2 5-lodoindirubine Yield: 80%, fine, deep-purple needles, Fp: 334-335 ° C (decomposition);
  • Mass spectrum: m/z 307 (M + , 5%), 276 (10%), 262 (100%), 234 (23%), 205 (22%), 158 (6%), 131 (10), 104 (19%), 76 (12%), 50 (6%).
  • lndirubine-3'-oxime was synthesized by reaction of indirubine with hydroxylamine hydrochloride in a pyridine solution (Farbtechnike vorm. Meister
  • Table 2 shows the structures of the compunds of Examples 1 to 11.
  • Table 3 shows the specificity of the compounds of Examples 1 to 1 1 (IC 50 . values given in ⁇ M) to inhibit cdc2 kinase in comparison to other cellular kinases.
  • ND not dedected
  • PKA cAMP-dependent protein kinase
  • PKC Ca 2 + - dependent protein kinase
  • Isoindigo was synthesized by reaction of oxindole with isatin in acetic acid with addition af hydrochloric acid (Wahl A., Bayard P., Comptes Rendues
  • Isoindigo shows an IC 50 -value of 80 ⁇ M for the p34 cdc2 /cyclinB complex.
  • Table 4 shows the kinase inhibition selectivity of indigo, indirubin, 5-chloroindi- rubine, indirubine-3'-monoxim and indirubine-5 sulfonic acid .
  • the indicated IC 50 values were calculated from respective dose response curves and are presented in ⁇ M. Tab. 4:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases, particularly CDK 1, CDK 2, CDK 4 and CDK 5, more particularly ATP:Proteinphosphotransferase p34<cdc2> (CDK1).

Description

"Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases"
Description
The present invention relates to the use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and CDK 5, more particularly ATP:Proteinphosphotransfer- ase p34cdc2 (CDK1 ) .
Indigoid bisindoles comprise a spectrum of natural dye stuffs. Many of these can be obtained from plants. Accordingly, indirubine, indigo and isoindigo are natural products which can be obtained from different plants: namely, Baphicacanthus cusia (Acanthaceae), Indigofera suffruticosa (Fabaceae), Isatis indigotica (Brassi- caceae) and others. Indican, a glycoside which is found in plants, gives glucose and 3-hydroxyindole due to acidic or enzymatic hydrolysis. 3-Hydroxyindole is converted by air-oxidation into indigo and its isomers. Indigo naturalis (Chinese: quingdai) is the natural blue dye obtained from plant material, e.g. Isatis indigotica (Brassicaceae) . Indirubine, an isomer of indigo, can be found in Indigo natura- Ms in an amount of up to 60% (Falbe J . & Regitz M., Rόmpp Chemie Lexikon
(1 992), 9. Aufl., Stuttgart, Georg Thieme Veriag) . It occurs also in Isatis tincto- ria in an amount of up to 5% which is indigenous to Central Europe (Gelius R., Z. Chem., 20, (1 980), 340-341 ) .
Indigo naturalis is reported to be used in traditional Chinese medicine εs a hemostatic, antipyretic, anti-inflammatory and sedative agent in the treatment of bacterial and viral infections. Antileukemic effects of Indigo naturalis have also been reported, with indirubine being the effective principle (Ji X. et al., Acta Pharm. Sin., 1 6, ( 1 981 ), 146-1 48; Gan W. J . et al., J . Hematol., 6, (1 985), 61 1 -61 3) . Furthermore, derivatives of indirubine are known for a long time as dyes of low persistence. Few, structurally quite different types of p34cdc2 inhibitors have been described up to now. They are either of natural origin or derived from natural compounds and show varying degrees of inhibitory activities. Examples are Staurosporine, an alkaloid from Streptomyces sp, Butyrolactone-I from Aspergillus terreus var., Flavopiridol, a novel promising anti-tumour agent derived by partial synthesis from a parent structure found in the indian plant Dysoxylum binectariferum, 9- Hydroxyellipticin from the plants Ochrosia elliptica and Ochrosia acuminata, the purine derivatives olomoucine, roscovitine and isopentenyladenine and some peptides. The mechanism of these compounds is based on competitive inhibition of ATP binding (Meijer , Trends in Cell Biology, 6, (1 996), 393-397) .
For determination of the IC 50-vaiues: p34cdc2/cyclin B was purified from M phase starfish (Marthasterias glacialis) oocytes by affinity chromatogaphy on p9CKShs1-Sepharose beads, from which it was eluted by free p9CKShs1 as described (Meijer et al., Eur. J. Biochem., 243, (1 997), 527-536) . It was assayed with 1 mg histone H 1 (Sigma type lll-S)/ml, in the presence of 1 5 μM |>-32P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 10 min. incubation at 30°C, 25 μl aliquots of supernatant were spotted onto 2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper, and after 20 sec, the filters v^re washed five times (for at least 5 min. each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters were transferred into 6 ml plastic scintillation vials, 5 ml ACS (Amersham) scintillation fluid was added and the radioactivity measured in a Packard scintillation counter. The kinase activity was expressed in pmoles phosphate incorporated into histone H 1 /10 min incubation or in % of maximal activity.
The strongest inhibitors of p34 are derivatives of staurosporine (IC 50
0,003-0,03 μM) . The selectivity of these inhibitors is, however, rather poor. They also show more or less potent inhibitory activity to quite a wide range of cellular kinases. Table 1 shows the specifity of known chemical inhibitors of cyclin-dependent kinases (IC50-values given in μM) (cf. Meijer L, Trends in Cell Biology, 6, ( 1 996), 393-397) . Tab. 1 :
Enzyme StauroUCN- Butyro- Flavopi- Olomo- Rosco- 9-Hydro- sporine 01 lactone- ridol ucin vitine xy-ellip- ticine
CDK1 0.003- 0.031 0.60 0.40 7 0.65a ca. 1 0.009
CDK2 0.007 0.030 1 .50 0.40 7 0.70 ND
CDK4 < 0.032 no 0.40 > 1 000 > 100 ND
1 0.000 effect
MAPK 0.020 0.910 94 ND 30 30 ND
PKA 0.008 ND 260 145 > 2000 > 1000 ND
PKG 0.009 ND ND 6 > 2000 > 1000 ND
PKC 0.005 0.007 1 60 ND > 1 000 > 100 ND
Tyrosine- 0.006 ND > 590 25 440 70 ND kinase (EGF-R) (EGF-R) (EGF-R) (EGF-R) (l-R)
0.006
(Src)
CDK: cyclin-dependent kinase; EGF-R: epidermal growth factor receptor tyrosine kinase; l-R: insulin receptor-tyrosine kinase;
MAPK: mitogene-activated protein kinase; ND: not determined;
PKA: cAMP-dependent protein kinase; PKG: cGMP-dependent protein kinase. aIC50-value for racemic mixture; IC50 for (R)-roscovitin is 0.45 μM.
Cyclins and cyclin dependent kinases (CDK) have an essential role for driving the cell through the cell cycle (cell division cycle, cdc) . During the cell division cycle, oscillations in concentrations and activities of cyclins are observed. This applies, e.g. to cyclins D and E in the so-called G 1 -phase of the cell cycle and to cyclinA (S- and M-Phase) and cycIinB (G2- and M-Phase) .
The cyclin dependent kinases are activated by association with a member of the cyclin-family. Up to now, eight human CDKs have been described: CDK1 ( = p34cdc2), CDK2 to CDK8. CDK-proteins consist of a catalytic subunit and a regulatory subunit, the cyclins (Meijer et al., Eur. J. Biochem., 243, ( 1 997), 527-536) . Every step of the cell division cycle is regulated by specific CDK/cyc- lin complexes which ascertain a strict control. Important checkpoints are at the transition from G 1 phase to S phase and from G2 phase to M phase (Pines J., Cancer Biology, 6, (1 995), 63-72). The p34cdc2/cyclinB complexes are important components at the G2-M-checkpoint.
Fig.1 shows the points of action of the cyclin CDK complex cdc2/cyclinB in the cell divsion cycle (M = mitosis, cell division; G = gap; S = synthesis; interphase = G^ S + G^.
The cdc2/cyclinB complexes are the primary active protein kinases in mitosis. They accumulate in an inactive state in the cytoplasm in interphase cells, and are then rapidly activated by cdc25 phosphatase and translocated into the nucleus at the beginning of mitosis (Pines J., Hunter J., Cell Biol., 1 1 5(1 ) , ( 1 991 ), 1 -1 7) . CyclinB is degraded at the metaphase-anaphase transition, inactivating cdc2, which is necessary for exit from mitosis (Glotzer et al., Nature, 349(6305). (1 991 ), 132-138; Murray A.W., Nature, 339(6222). (1 989), 280-286; Surana U. et al., Cell, 65(1). (1 991 ), 145-1 61 ) . Multiple changes of
CDK proteins and their regulators are associated with the development of human tumours (Cordon-Cardo C, Am. J. Pathol., 147(3), (1 995), 545-560) .
Thus, the technical problem underlying the present invention is to provide new inhibitors for cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and
CDK 5, more particularly ATP:Proteinphosphotransferase p34cdc2 (CDK1 ), which exhibit a high selectivity as well as high efficiency compared to the inhibitors known in the art.
The solution to the above technical problem is achieved by the embodiments characterized in the claims.
In particular, the present invention relates to the use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases, particularly CDK 1 , CDK2, CDK 4 and CDK 5, more particularly
ATP:Proteinphosphotransferase p34cdc2 (CDK1 ), in mammals, preferably in man. Preferably, the indigoid bisindole derivatives are selected from indigo derivatives, isoindigo derivatives or indirubine derivatives. In a preferred embodiment of the present invention, the indirubine derivate is a compound having the general formula (I)
Figure imgf000007_0001
(I)
wherein the groups R1 and R6 can be the same or different and represent a hydrogen atom; a halogen atom; a hydroxy group; a methylenehydroxy group; a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain alkyloxy group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain methylenealkoxy group having 1 to 18 carbon atoms; a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; a substituted or unsubstituted aralkyl group which can comprise one or more heteroatoms; a substituted or unsubstituted aryloxy group which can comprise one or more heteroatoms; a mono-, di- or trialkylsilyl group having 1 to 6 carbon atoms independently of each other in each instance in the straight-chain or branched-chain alkyl group; a mono-, di- or triarylsilyl group with substituted or unsubstituted aryl groups independently of each other in each instance; a trifluoromethyl group; a -COM group; a -COOM group; a -CH2COOM group, wherein M is hydrogen, a straight- chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, or an aryl group which can comprise one or more heteroatoms and can be substituted with one or more halogen atoms, one or more alkyl groups or one or more alkoxy groups; a -NR11R12 group, wherein R1 1 and R12 can be the same or different and represent a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; or an acyl group; a methylene-amino group -CH2-NR11 R12, wherein R1 1 and R12 have the above definitions; a benzyl group, wherein the benzene nucleus can comprise one or more heteroatoms; a methylenecycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a physiological amino acid residue bound to the nitrogen as an amide; an O-glycoside or a N-glycoside, wherein the glycoside is selected from monosaccharides or disaccharides; or a methylenesulfonate group; R2, R3, R4, R5, R7, R8, R9 and R10 can be the same or different and represent a hydrogen atom; a halogen atom; a hydroxy group; a nitroso group; a nitro group; an alkoxy group; a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups; a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; a substituted or unsubstituted aralkyl group which can comprise one or more heteroatoms; a substituted or unsubstituted aryloxy group which can comprise one or more heteroatoms; a substituted or unsubstituted methylenearyloxy group which can comprise one or more heteroatoms; a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a methylenecycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a trifluoromethyl group; a -COM group; a -COOM group; a -CH2COOM group, wherein M is hydrogen, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, or an aryl group which can comprise one or more heteroatoms and can be substituted with one or more halogen atoms, one or more alkyl groups or one or more alkoxy groups; a -NR 1R12 group, wherein R1 1 and R12 can be the same or different and represent a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms, or an acyl group, or wherein the nitrogen atom is part of a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatom(s); a -CONR1 1 R12 group, wherein R1 and R12 have the above definitions; a hydroxylamino group; a phosphate group; a phosphonate group; a sulfate group; a sulfonate group; a sulfonamide group; a -S02NR11R12 group, wherein R11 and R12 have the above definitions; an azo group -N = N-R13, in which R13 represents an aromatic system which can be substituted by one or more carboxyl groups, phosphoryl groups or sulfonate groups; or a O-glycoside or a N-glycoside, wherein the glycoside is selected from monosaccharides or disaccharides; or R1 and R5, and R6 and R10, respectively, form independently from each other a ring together having 1 to 4, optionally substituted, CH2 groups; and X and Y can be the same or different and represent an oxygen atom; a sulfur atom; a selenium atom; a tellurium atom; a NR14 group in which the group R14 represents a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 18 carbon atoms which can be substituted by one or more carboxyl groups, phosphoryl groups or sulfonate groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms, an aralkyl group, or a sulfonate group; or a NOR14 group, wherein the group R14 has the above definitions.
With respect to the benzene nuclei constituting the indirubine derivates of the the above general formula (I) one or more ring atoms can be replaced by nitrogen atoms. Further, one or more aromatic or non-aromatic ring systems which can comprise one or more heteroatoms independently of each other, can be condensed to the indirubine system. Furthermore, the indirubine derivatives having the above general formula (I) can also be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
In another embodiment of the present invention, the isoindigo derivate is a compound having the general formula (II)
Figure imgf000009_0001
wherein R1 to R14 and X and Y have the above definitions.
With respect to the benzene nuclei constituting the isoindigo derivates of the above general formula (II) one or more ring atoms can be replaced by nitrogen atoms. Further, one or more aromatic or non-aromatic ring systems which can comprise one or more heteroatoms independently of each other, can be condensed to the isoindigo system. Furthermore, the isoindigo derivatives having the above general formula (II) can be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
In a further embodiment of the present invention, the indigo derivate is a compound having the general formula (III)
Figure imgf000010_0001
(III)
wherein R1 to R14 and X and Y have the above definitions.
With respect to the benzene nuclei constituting the indigo derivates of the above general formula (III) one or more ring atoms can be replaced by nitrogen atoms. Further, one or more aromatic or non-aromatic ring systems which can comprise one or more heteroatoms independently of each other, can be condensed to the indigo system. Furthermore, the indigo derivatives having the above general formula (III) can be bound to a polyethyleneglycolester or a polyethyleneglycolether by ester bondings or ether bondings, respectively.
The above indigoid bisindole derivatives having the general formulas (l), (II) or (III) can also be in the form of their physiologically acceptable salts.
In the search for new selective inhibitors of cellular signalling pathways, it has surprisingly been found that indigoid bisindole derivatives are highly selective inhibitors of the enzyme complex p34cdc2/cyclinB. An inhibition of p34cdc2-kinase by indigoid bisindole derivatives is not described in the prior art. Surprisingly, it has turned out that indigoid bisindole derivatives are both highly selective and highly effective inhibitors of cdc2-kinase and other cyclin dependent kinases (CDK's), showing IC50-values with the isolated enzyme down to submicromolar range. The inhibition of CDK-activities also is observed in cell culture, using human tumor cell lines. As an example, indirubin-3'-monoxime was found to inhibit histone H 1 phosphorylation as a measure for CDK1 /cyclin B activity after 24 h incubation of MCF-7 mammary carcinoma cells. Moreover, the content of cyclin B complex was significantly reduced. Cells arrested by serum deprivation after treatment for 24 h with indirubin-3'-monoxime in serum containing medium exhibited an arrest in G 1 -phase of the cell cycle at low micromolar concentrations of the substance. In concentrations > 5 μM, an additional arrest at G2/M-phase of the cell cycle became apparent. Cells arrested in G2/m by Nocodazole treatment after release of the block exhibited a significant increase of G2/M arrested cells under treatment with > 5 μM indirubin-3'-monoxime, resulting in a massive accumulation of cells in G2/M. Concomitantly with the observed intracellular effects, growth inhibition was induced in the same concentration range, resulting in an IC50-value of 3.3 ± 0.7 μM after 3 days incubation (IC50 = concentration that induces 50% growth inhibition as compared to vehicle control) . In addition, induction of apoptotic cell death was observed.
Based on the above mentioned selective inhibitory potency down to the nanomolar range, indirubine derivatives can be used for analytical biochemistry, especially for the study of cell cycle effects. Furthermore, these compounds can be used for the treatment of diseases in patients, which are connected to the loss of proliferation control without any restriction to these potential areas of application. These include cancers, psoriasis, cardiovascular diseases (stenosis, restenosis) (Brooks et al., J. Biol. Chem., 272, ( 1 997), 29207-2921 - 1 ), infectious diseases (unicellular parasites (Trypanosoma, Toxoplasma, Plasmodium, etc.), fungi, etc.), nephrology (glomerulonephritis: Pippin et al., J. Gin. Invest., 100, ( 1 997), 251 2-2520), neurodegenerative disorders such as Alzheimer disease (Imahori, K., Uchida T., J. Biochem., 1 21 , ( 1 997), 1 79-1 88), viral infections such as cytomegalovirus (Bresnahan W. A. et al., Virology 231,(1 997), 239-247) and HIV (Mancebo H.S.Y. et al., Genes & Dev., H, (1 997), 2633-2644) .
The present invention is explained further by the following examples:
Example 1 : Synthesis of indirubine
To a solution of 0.42 g (2.4 mmol) of indoxyl acetate in 20 ml methanol under argon 0.35 g (2.4 mmol) of isatin and 0.55 g (5.2 mmol) of sodium carbonate are added. The mixture is stirred for 30 min at ambient temperature. After 24 h standing at ambient temperature, the reaction mixture is filtered off. The precipitate is washed with little methanol and water until the filtrate shows a neutral pH. Residual water is removed by storage in an evacuated exsiccator over potassium hydroxide. Recrystallisation from ethanol or pyridine gives deep purple crystals (Russell G.A., Kaupp G. ( 1 969), J. Am. Chem. Soc, 9JL, 3851 -
9, modified) .
Yield: 0.51 g (81 %), fine, deep-purple needles, Fp: 341 -343 ° C
CHN-analysis: (C16H10N2O2); MW: 262,26 g/mol; calc: 73.3% C, 3.8% H, 10.7% N; found: 73.2% C, 4.0% H, 10.6% N mass spectrum: m/z = 262: (M + , 100%), 234: (43%), 205 (25%), 1 58 (3%),
1 31 (4%), 1 03 (7%), 76 (3%)
1 H-NMR and 13C-NMR-spectrum are in accordance with the proposed structure.
IR-spectrum: 3340 cm"1 : v (N-H), 1 710 cm"1 : v (3 '-C = O), 1 650 cm"1: v (2- C = 0), 1 590 cm-1 : v (C = C, aryl), 1450 cm"1 : v (C = C, aryl), 745 crτr1 : v (aryl with four neighbouring H-atoms) .
UV/Vis-spectrum (DMSO): 290 nm, 363 nm, 383 nm (shoulder), 551 nm Essentially the same synthetic procedere was applied for the following Examples 2 to 9 and 1 1 and 1 2:
Example 2: 5-lodoindirubine Yield: 80%, fine, deep-purple needles, Fp: 334-335 ° C (decomposition);
CHN-analysis (C16H9IN202); MG = 388.1 6 g/mol; calc : 49.5% C, 2.3% H, 7.2% N; found. : 49.7% C, 2.5% H, 7.1 % N;
Mass spectrum: 388 (M + , 1 00%), 360 (3%), 269 (9%), 261 (6%), 233 ( 1 6%), 205 ( 1 6%), 1 28 (1 %); 1 H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
UV/Vis-spectrum (DMSO): 370 nm, 386 nm (shoulder), 555 nm.
Example 3: 5-Bromoindirubine
Yield: 70%, fine, deep-purple needles; CHN-analysis (C16H9BrN2O2); MG = 341 .1 6 g/mol, calc: 56.3% C, 2.7% H,
8.2% N; found 56.4% C, 2.7% H, 8.2% N;
Mass spectrum: 342(M + , 100%), 340 (M + , 99%), 314 (18%), 262 (64%),
233 (34%), 205 (81 %), 1 77 (10%);
1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 4: 5-Chloroindirubine
Yield: 95%, fine, deep-purple needles;
CHN-analysis (C16H9CIN202); MG = 296.70 g/mol; calc: 49.5% C, 2.3% H,
7.2% N; found: 49.7% C, 2.5% H, 7.1 % N; Mass spectrum: m/z = 296 (M + , 1 00%), 268 (39%), 239 (8%), 233 (35%),
205 (50%), 1 77 (7%), 1 53 (6%), 1 37 (7%), 77 (7%), 1 20 (4%), 1 02 (6%),
77 (7%) .
1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 5: 5-Fluoroindirubine
Yield: 92%, fine, deep-purple needles;
CHN-analysis (C16H9FN202), MG = 280.25 g/mol, calc: 68.6% C, 3.2% H,
9.9% N; found: 68.0%C, 3.2% H, 9.9% N; Mass spectrum: m/z = 281 (M+ + H + , 19%), 280 (M + , 100%), 252 (73%), 223 (32%), 176 (6%), 140 (7%), 121 (13%), 94 (4%), 76 (12%), 77 (7%), 57 (4%), 44(15%).
1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 6: 5-Methylindirubine: Yield: 92%, fine, deep-purple needles;
CHN-analysis (C17Hl2N202), MG = 276.28 g/mol, calc: 73.9% C, 4.4% H, 10.1% N; found: 73.8%C, 4.3% H, 10.2% N; Mass spectrum: m/z = 276 (M+, 100%), 261 (10%), 248 (47%), 247 (53%),
220 (6%), 219 (18%), 205 (7%), 171 (4%), 165 (10%), 138 (4%), 133 (15%), 104 (7%), 77 (7%); 1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 7: 5-Nitroindirubine
Yield: 88%, fine, deep-purple needles;
CHN-analysis (C16H9N304), MG = 307.26 g/mol; calc: 62.5% C, 3.0% H,
13.7% N; found: 62.4%C, 3.0% H, 13.3% N;
Mass spectrum: m/z = 307 (M + , 5%), 276 (10%), 262 (100%), 234 (23%), 205 (22%), 158 (6%), 131 (10), 104 (19%), 76 (12%), 50 (6%).
1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 8: 5'-Bromoindirubine Yield: 92%, fine, deep-purple needles; CHN-analysis (C16H9BrN202), MG = 341.16 g/mol, calc: 56.3% C, 2.7% H,
8.2% N; found: 55.7%C, 2.5% H, 8.0% N. 1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 9: 5,5'-Dibromoindirubine Yield: 94%, fine, deep-purple needles;
CHN-analysis (C16H8Br2N202), MG = 420.06 g/mol; calc: 45.7% C, 1.9% H, 6.7% N; found: 45.8% C, 2.0% H, 6.4% N. 1H-NMR-spectrum is in accordance with the proposed structure. Example 10: lndirubine-3'-oxime
lndirubine-3'-oxime was synthesized by reaction of indirubine with hydroxylamine hydrochloride in a pyridine solution (Farbwerke vorm. Meister
Lucius & Brϋning in Hoechst a.M., Patentschrift des Reichspatentamtes Nr.
283726 (1913)). 13C-NMR-spectroscopy revealed the location of the hydroxyimino residue in 3'-Position (<J(C2) = 171.05 ppm; c5(C3') = 145.42 ppm; DMSO-d6, RT)
Yield: 90 %, red crystals;
CHN-analysis (C16Hl1N3O2), MG = 277.30g/mol; calc: 69.3% C, 4.0% H, 15.2
% N; found: 69.0% C, 4.0% H, 14.9% N;
1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Example 11 : lndirubine-5-sulfonic acid
Yield: 76%, crystalline, deep-purple substance;
Mass spectrum: 388 (M + , 100%), 360 (3%), 269 (9%), 261 (6%), 233
(16%), 205 (16%), 128 (1%). 1H-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Table 2 shows the structures of the compunds of Examples 1 to 11.
Tab. 2:
Figure imgf000016_0001
Table 3 shows the specificity of the compounds of Examples 1 to 1 1 (IC50. values given in μM) to inhibit cdc2 kinase in comparison to other cellular kinases.
Tab. 3:
Figure imgf000016_0002
ND: not dedected; PKA: cAMP-dependent protein kinase; PKC: Ca2 + - dependent protein kinase
Example 1 2: Isoindigo
Figure imgf000017_0001
Isoindigo was synthesized by reaction of oxindole with isatin in acetic acid with addition af hydrochloric acid (Wahl A., Bayard P., Comptes Rendues
Hebdomadaires des Seances de L'Academie des Sciences, 148, ( 1 909), 71 6-
71 9) . Yield: 84%, crystalline, brown substance;
CHN-analysis (C16H10N202), MG = 262.26 g/mol; calc: 73,3% C, 3.8% H,
10,7%o N; found: 73.0% C, 3.8% H, 1 0.9% N;
Mass spectrum: m/z = 262 (M + , 1 00%), 234 (85%), 220 (5%), 205
(1 8%), 1 90 (4%), 1 77 (5%), 1 51 (5%), 1 32 ( 1 7%), 103 (6%), 76 (4%), 32 (26%) .
^-NMR- and 13C-NMR-spectrum are in accordance with the proposed structure.
Isoindigo shows an IC50-value of 80μM for the p34cdc2/cyclinB complex.
Table 4 shows the kinase inhibition selectivity of indigo, indirubin, 5-chloroindi- rubine, indirubine-3'-monoxim and indirubine-5 sulfonic acid . The indicated IC50 values were calculated from respective dose response curves and are presented in μM. Tab. 4:
Figure imgf000018_0001

Claims

Claims
1 . Use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin dependent kinases.
2. Use according to claim 1 , wherein the cyclin dependent kinases are selected from CDK 1 , CDK 2, CDK 4 or CDK5.
3. Use according to claim 1 or 2, wherein the indogoid bisindole derivatives are selected from indigo derivatives, isoindigo derivatives or indirubine derivatives.
4. Use according to claim 3, wherein the indirubine derivate is a compound having the general formula (I)
Figure imgf000019_0001
(I)
wherein the groups R1 and R6 can be the same or different and represent a hydrogen atom; a halogen atom; a hydroxy group; a methylenehydroxy group; a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain alkyloxy group having 1 to 1 8 carbon atoms; a straight-chain or branched-chain methylenealkoxy group having 1 to 1 8 carbon atoms; a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; a substituted or unsubstituted aralkyl group which can comprise one or more heteroatoms; a substituted or unsubstituted aryloxy group which can comprise one or more heteroatoms; a mono-, di- or trialkylsilyl group having 1 to 6 carbon atoms independently of each other in each instance in the straight-chain or branched-chain alkyl group; a mono-, di- or triarylsilyl g roup with substituted or unsubstituted aryl groups independently of each other in each instance; a trifluoromethyl group; a -COM group; a -COOM group; a -CH2COOM group, wherein M is hydro- gen, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, or an aryl group which can comprise one or more heteroatoms and can be substituted with one or more halogen atoms, one or more alkyl groups or one or more alkoxy groups; a -NR1 1R12 group, wherein R11 and R12 can be the same or different and represent a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; or an acyl group; a methyleneamino group -CH2-NR11R12, wherein R1 1 and R12 have the above definitions; a benzyl group, wherein the benzene nucleus can comprise one or more heteroatoms; a methylenecycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a physiological amino acid residue bound to the nitrogen as an amide; an O-glycoside or a N-glycoside, wherein the glycoside is selected from monosaccharides or disaccharides; or a methylenesulfonate group; R2, R3, R4, R5, R7, R8, R9 and R10 can be the same or different and represent a hydrogen atom; a halogen atom; a hydroxy group; a nitroso group; a nitro group; an alkoxy group; a straight- chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups; a substituted or unsubstituted aryl group which can comprise one or more heteroatoms; a substituted or unsubstituted aralkyl group which can comprise one or more heteroatoms; a substituted or unsubstituted aryloxy group which can comprise one or more heteroatoms; a substituted or unsubstituted methylenearyloxy group which can comprise one or more heteroatoms; a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a methylenecycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatoms; a trifluoromethyl group; a -COM group; a -COOM group; a -CH2COOM group, wherein M is hydrogen, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, or an aryl group which can comprise one or more heteroatoms and can be substituted with one or more halogen atoms, one or more alkyl groups or one or more alkoxy groups; a -NR1 1R12 group, wherein R11 and R12 can be the same or different and represent a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can additionally carry one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms, or an acyl group, or wherein the nitrogen atom is part of a cycloalkyl group having 3 to 7 carbon atoms which can comprise one or more heteroatom(s); a -CONR1 1 R12 group, wherein R 1 and R 2 have the above definitions; a hydroxylamino group; a phosphate group; a phosphonate group; a sulfate group; a sulfonate group; a sulfonamide group; a -S02NR11 R12 group, wherein R1 1 and R12 have the above definitions; an azo group -N = N-R13, in which R13 represents an aromatic system which can be substituted by one or more carboxyl groups, phosphoryl groups or sulfonate groups; or a O-glycoside or a N-glycoside, wherein the glycoside is selected from monosaccharides or disaccharides; or R1 and R5, and R6 and R10, respectively, form independently from each other a ring together having 1 to 4, optionally substituted, CH2 groups; and X and Y can be the same or different and represent an oxygen atom; a sulfur atom; a selenium atom; a tellurium atom; a NR14 group in which the group R14 represents a hydrogen atom, a straight-chain or branched-chain alkyl group having 1 to 1 8 carbon atoms which can be substituted by one or more carboxyl groups, phosphoryl groups or sulfonate groups, a substituted or unsubstituted aryl group which can comprise one or more heteroatoms, an aralkyl group, or a sulfonate group; or a NOR14 group, wherein the group R14 has the above definitions.
5. Use according to claim 4, wherein one or more ring atoms of the benzene nuclei of the compound having the general formula (I) are replaced by nitrogen atoms.
6. Use according to claim 4 or 5, wherein one or more aromatic or non- aromatic ring systems which can comprise one or more heteroatoms independently of each other, are condensed to the indirubine system.
7. Use according to anyone of claims 4 to 6, wherein the compound having the general formula (I) is bound to a polyethyleneglycolester or a polyethyleneglycolether.
8. Use according to claim 3, wherein the isoindigo derivate is a compound having the general formula (II)
Figure imgf000022_0001
(ID
wherein R to R and X and Y have the meanings as defined in claim 4.
9. Use according to claim 8, wherein one or more ring atoms of the benzene nuclei of the compound having the general formula (II) are replaced by nitrogen atoms.
0. Use according to claim 8 or 9, wherein one or more aromatic or non- aromatic ring systems which can comprise one or more heteroatoms independently of each other, are condensed to the isoindigo system.
1 . Use according to anyone of claims 8 to 1 0, wherein the compound having the general formula (II) is bound to a polyethyleneglycolester or a polyethyleneglycolether.
2. Use according to claim 3, wherein the indigo derivate is a compound having the general formula (III)
Figure imgf000023_0001
(III)
wherein R1 to R14 and X and Y have the meanings as defined in claim 4.
3. Use according to claim 1 2, wherein one or more ring atoms of the benzene nuclei of the compound having the general formula (111) are replaced by nitrogen atoms.
4. Use according to claim 1 2 or 1 3, wherein one or more aromatic or non- aromatic ring systems which can comprise one or more heteroatoms independently of each other, are condensed to the indigo system.
5. Use according to anyone of claims 1 2 to 1 4, wherein the compound having the general formula (III) is bound to a polyethyleneglycolester or a polyethyleneglycolether.
6. Use according to anyone of claims 1 to 1 5, wherein the indigoid bisindole derivative is in the form of a physiologically acceptable salt.
7. Compound which is 5-fluoroindirubine.
8. Compound which is 5-nitroindirubine.
9. Compound which is 5,5'-dibromoindirubine.
PCT/EP1999/003625 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases Ceased WO1999062503A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HU0102240A HUP0102240A3 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
JP2000551759A JP2002516851A (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament for inhibiting cyclin-dependent kinases
AU43687/99A AU762830B2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
CA002333661A CA2333661A1 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
DK99926420T DK1079826T3 (en) 1998-05-29 1999-05-26 Use of Indigoidal Bisindole Derivatives for the Preparation of a Drug for Inhibition of Cyclin-dependent Kinases
EP99926420A EP1079826B1 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
KR1020007013499A KR20010078722A (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
BR9910810-0A BR9910810A (en) 1998-05-29 1999-05-26 Use of derivatives of indigoid bisindoles
IL13991499A IL139914A0 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
AT99926420T ATE233560T1 (en) 1998-05-29 1999-05-26 USE OF INDIGO-LIKE BISINDOLES FOR PRODUCING A DRUG FOR INHIBITING CYCLIN DEPENDENT KINASES
DE69905712T DE69905712T2 (en) 1998-05-29 1999-05-26 USE OF INDIGO-LIKE BISINDOLES FOR PRODUCING A MEDICINAL PRODUCT FOR INHIBITING CYCLINE-DEPENDENT KINASES
NO20006027A NO20006027L (en) 1998-05-29 2000-11-28 Use of Indigoid-Bisindole Derivatives for the Preparation of a Medication to Inhibit Cyclin-dependent Kinases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98109845A EP0966963A1 (en) 1998-05-29 1998-05-29 Use of indigoid bisindole derivatives as CDK1 inhibitors
EP98109845.2 1998-05-29
EP99105693 1999-03-19
EP99105693.8 1999-03-19

Publications (2)

Publication Number Publication Date
WO1999062503A2 true WO1999062503A2 (en) 1999-12-09
WO1999062503A3 WO1999062503A3 (en) 2000-01-27

Family

ID=26149292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003625 Ceased WO1999062503A2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Country Status (14)

Country Link
EP (1) EP1079826B1 (en)
JP (1) JP2002516851A (en)
KR (1) KR20010078722A (en)
AT (1) ATE233560T1 (en)
AU (1) AU762830B2 (en)
BR (1) BR9910810A (en)
CA (1) CA2333661A1 (en)
DE (1) DE69905712T2 (en)
DK (1) DK1079826T3 (en)
ES (1) ES2194468T3 (en)
HU (1) HUP0102240A3 (en)
IL (1) IL139914A0 (en)
NO (1) NO20006027L (en)
WO (1) WO1999062503A2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
US6350747B1 (en) 1999-03-04 2002-02-26 Glaxo Wellcome Inc. 3-(anilinomethylene) oxindoles
DE10053474A1 (en) * 2000-10-24 2002-05-02 Schering Ag Indirubin derivatives containing sulfur, their production and use
WO2000061124A3 (en) * 1999-04-12 2002-05-02 Heinz Herbert Fiebig Use off cell membrane penetrating indigoid bisindole derivatives
WO2002030410A3 (en) * 2000-10-10 2002-07-11 Univ Texas Suppression of cyclin kinase activity for prevention and treatment of infections
DE10061162A1 (en) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituted indirubin derivatives, their preparation and use
FR2821358A1 (en) * 2001-02-27 2002-08-30 Aventis Pharma Sa OXINDOLES INHIBITORS OF CDK-1 AND THEIR THERAPEUTIC APPLICATION
WO2002092079A1 (en) * 2001-05-17 2002-11-21 Schering Aktiengesellschaft Utilization of selective indirubin derivatives as vegf-r inhibitors
DE10129028A1 (en) * 2001-06-11 2003-01-02 Schering Ag Soluble Cdk-inhibitory Indirubin Derivatives
WO2002059123A3 (en) * 2000-12-18 2003-02-06 Us Gov Health & Human Serv Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
WO2002074742A3 (en) * 2001-03-16 2003-02-20 Schering Ag Cdk-inhibitory indirubin derivatives having an increased solubility
WO2003027275A1 (en) * 2001-09-27 2003-04-03 Alcon, Inc. Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
WO2003051900A1 (en) * 2001-12-13 2003-06-26 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
WO2004039797A1 (en) * 2002-10-29 2004-05-13 Jingcai Cheng A special kind of indole compounds, their preparation, and their use in treatment and prevention of those disease such as cancer
WO2005070416A1 (en) * 2004-01-27 2005-08-04 Anygen Co., Ltd. Indirubin derivatives having anticancer property against human cancer cell me
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
WO2006010628A1 (en) * 2004-07-29 2006-02-02 Creabilis Therapeutics S.P.A. Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies
WO2007081060A1 (en) * 2006-01-16 2007-07-19 Japan Science And Technology Agency Therapeutic agent for neuropathic pain
CN1329376C (en) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 Preparation method and medical uses of N(1)-hydrocarbyl-3'-nitrotylindirubin derivative 1
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
WO2010072399A1 (en) 2008-12-22 2010-07-01 Gerhard Eisenbrand 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament
US7855223B2 (en) 2004-01-12 2010-12-21 Natrogen Therapeutics International, Inc. Method of treating inflammatory arthritis
FR2952818A1 (en) * 2009-11-23 2011-05-27 Oreal Composition, useful for dyeing keratin fibers, preferably human keratin fibers such as hair, comprises one or more dye precursors comprising indole derivative, dyes comprising indoline dione compounds and organic compounds in a medium
WO2011096676A2 (en) 2010-02-05 2011-08-11 Anygen Co., Ltd. Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US10383847B2 (en) 2012-03-23 2019-08-20 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN113773243A (en) * 2021-09-01 2021-12-10 大连理工大学 Method for preparing isoindigo compounds by organic catalytic oxidation of indole self-condensation
CN115925610A (en) * 2022-12-05 2023-04-07 天津中医药大学 6,6' -diisopentenyl indirubin and preparation method and application thereof
US11834412B2 (en) 2021-10-08 2023-12-05 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009434A (en) * 2002-04-03 2005-01-25 Allergan Inc (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors.
FR2945747A1 (en) 2009-05-25 2010-11-26 Centre Nat Rech Scient ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING A CDKS INHIBITOR AND A CELL GROWTH INHIBITOR
US8524121B2 (en) * 2012-01-27 2013-09-03 Xerox Corporation Bi-indoline-dithione polymers
CN103333161B (en) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 The preparation of 1 '-oxo Indirubin and purposes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (en) * 1984-06-20 1986-01-13 Isukura Sangyo Kk Bisindolinone and carcinostatic agent consisting essentially of same
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818632B2 (en) 1999-03-04 2004-11-16 Smithkline Beecham Corporation 3-(anilinomethylene)oxindoles
US6350747B1 (en) 1999-03-04 2002-02-26 Glaxo Wellcome Inc. 3-(anilinomethylene) oxindoles
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6815439B2 (en) 1999-03-04 2004-11-09 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US7129253B2 (en) 1999-03-04 2006-10-31 Smithkline Beecham Corporation Compounds
US6664285B1 (en) 1999-04-12 2003-12-16 Gerhard Eisenbrand Use of cell membrane penetrating indigoid bisindole derivatives
WO2000061124A3 (en) * 1999-04-12 2002-05-02 Heinz Herbert Fiebig Use off cell membrane penetrating indigoid bisindole derivatives
US6987092B1 (en) 1999-04-12 2006-01-17 Faustus Forschungs Cie. Translational Cancer Research Gmbh Indigoid bisindole derivatives
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2002030410A3 (en) * 2000-10-10 2002-07-11 Univ Texas Suppression of cyclin kinase activity for prevention and treatment of infections
WO2002034717A1 (en) * 2000-10-24 2002-05-02 Schering Aktiengesellschaft Sulphur-containing indirubin derivatives, production and use thereof
DE10053474A1 (en) * 2000-10-24 2002-05-02 Schering Ag Indirubin derivatives containing sulfur, their production and use
DE10061162A1 (en) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituted indirubin derivatives, their preparation and use
WO2002059123A3 (en) * 2000-12-18 2003-02-06 Us Gov Health & Human Serv Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
FR2821358A1 (en) * 2001-02-27 2002-08-30 Aventis Pharma Sa OXINDOLES INHIBITORS OF CDK-1 AND THEIR THERAPEUTIC APPLICATION
WO2002068411A1 (en) * 2001-02-27 2002-09-06 Aventis Pharma S.A. Cdk-1 inhibitor oxindoles and the application thereof in therapeutics
WO2002074742A3 (en) * 2001-03-16 2003-02-20 Schering Ag Cdk-inhibitory indirubin derivatives having an increased solubility
DE10125763A1 (en) * 2001-05-17 2002-11-28 Schering Ag New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
WO2002092079A1 (en) * 2001-05-17 2002-11-21 Schering Aktiengesellschaft Utilization of selective indirubin derivatives as vegf-r inhibitors
DE10129028A1 (en) * 2001-06-11 2003-01-02 Schering Ag Soluble Cdk-inhibitory Indirubin Derivatives
WO2003027275A1 (en) * 2001-09-27 2003-04-03 Alcon, Inc. Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US7598288B2 (en) 2001-09-27 2009-10-06 Alcon, Inc. Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
RU2297243C2 (en) * 2001-09-27 2007-04-20 Алькон, Инк. Inhibitors of glycogen synthase kinase-3 (gsk-3) in glaucoma treatment
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US6933315B2 (en) * 2001-12-13 2005-08-23 Longgui Wang Derivatives of isoindigo, indigo and indirubin and methods of treating cancer
WO2003051900A1 (en) * 2001-12-13 2003-06-26 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
WO2004039797A1 (en) * 2002-10-29 2004-05-13 Jingcai Cheng A special kind of indole compounds, their preparation, and their use in treatment and prevention of those disease such as cancer
US7855223B2 (en) 2004-01-12 2010-12-21 Natrogen Therapeutics International, Inc. Method of treating inflammatory arthritis
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
WO2005070416A1 (en) * 2004-01-27 2005-08-04 Anygen Co., Ltd. Indirubin derivatives having anticancer property against human cancer cell me
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
EA012602B1 (en) * 2004-05-12 2009-10-30 Байер Кропсайенс Аг Plant growth regulation
WO2006010628A1 (en) * 2004-07-29 2006-02-02 Creabilis Therapeutics S.P.A. Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies
CN1329376C (en) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 Preparation method and medical uses of N(1)-hydrocarbyl-3'-nitrotylindirubin derivative 1
WO2007081060A1 (en) * 2006-01-16 2007-07-19 Japan Science And Technology Agency Therapeutic agent for neuropathic pain
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
WO2010072399A1 (en) 2008-12-22 2010-07-01 Gerhard Eisenbrand 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament
FR2952818A1 (en) * 2009-11-23 2011-05-27 Oreal Composition, useful for dyeing keratin fibers, preferably human keratin fibers such as hair, comprises one or more dye precursors comprising indole derivative, dyes comprising indoline dione compounds and organic compounds in a medium
EP2531488A4 (en) * 2010-02-05 2013-07-24 Anygen Co Ltd INDIRUBIN-3'-OXIME DERIVATIVES AS POWERFUL INHIBITORS OF KINASES DEPENDENT ON CYCLINES
WO2011096676A2 (en) 2010-02-05 2011-08-11 Anygen Co., Ltd. Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
US10383847B2 (en) 2012-03-23 2019-08-20 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
CN113773243A (en) * 2021-09-01 2021-12-10 大连理工大学 Method for preparing isoindigo compounds by organic catalytic oxidation of indole self-condensation
CN113773243B (en) * 2021-09-01 2023-01-06 大连理工大学 Method for preparing isoindigo compounds by organic catalytic oxidation of indole self-condensation
US11834412B2 (en) 2021-10-08 2023-12-05 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists
US12516022B2 (en) 2021-10-08 2026-01-06 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists
CN115925610A (en) * 2022-12-05 2023-04-07 天津中医药大学 6,6' -diisopentenyl indirubin and preparation method and application thereof

Also Published As

Publication number Publication date
EP1079826A2 (en) 2001-03-07
AU4368799A (en) 1999-12-20
CA2333661A1 (en) 1999-12-09
HUP0102240A2 (en) 2001-11-28
ES2194468T3 (en) 2003-11-16
JP2002516851A (en) 2002-06-11
NO20006027L (en) 2001-01-22
DK1079826T3 (en) 2003-06-23
WO1999062503A3 (en) 2000-01-27
DE69905712D1 (en) 2003-04-10
DE69905712T2 (en) 2004-01-29
EP1079826B1 (en) 2003-03-05
KR20010078722A (en) 2001-08-21
ATE233560T1 (en) 2003-03-15
AU762830B2 (en) 2003-07-03
IL139914A0 (en) 2002-02-10
NO20006027D0 (en) 2000-11-28
HUP0102240A3 (en) 2003-05-28
BR9910810A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
AU762830B2 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
EP1308447B1 (en) Purine derivative for use in the treatment of a proliferative disorder
US6617331B2 (en) Purine inhibitors of protein kinases, G proteins and polymerases
US6239161B1 (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
TR200003515T2 (en) Substituted indolinone, their manufacture and use as medicines
UA66810C2 (en) 4-aminotiazole derivatives and compositions based thereon as inhibitors of cyclin-dependent kinases
KR20040062591A (en) Treatment of acute myeloid leukemia with indolinone compounds
CA2385105A1 (en) Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
JP2003514850A (en) Use of indirubin derivatives to prepare drugs
US5464835A (en) Use for bis-heterocyclic compounds and pharmaceutical compositions containing same
EP1218004B1 (en) 5-methyl indirubin for use in the treatment of human solid tumors
EP3661935A1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
EP0966963A1 (en) Use of indigoid bisindole derivatives as CDK1 inhibitors
EP3497083B1 (en) Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including cushing disease
MXPA00011751A (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
ES2307059T3 (en) USEFUL BISINDOLILMALEIMIDAS TO TREAT PROSTATE CANCER AND DISEASES MEDIATED BY AKT.
EP4393908A1 (en) Bis-pyrazolyl-methane compounds affecting kras
KR100399345B1 (en) Cyclin-dependent kinases inhibitor having aminonaphtoquinone structure
AU697120C (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
XIAO Agents for Hepatocellular Carcinoma: Synthesis and Mode of Action
WO2005113561A1 (en) Cyclicsulfonate pyrrole indolinones as kinase inhibitors
ZA200108378B (en) Use of cell membrane penetrating indigoid bisindole derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 43687/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 139914

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 09722605

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2333661

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011751

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020007013499

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999926420

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200007798

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1999926420

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007013499

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999926420

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 43687/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007013499

Country of ref document: KR